Review
. 2012 Mar; 30(14):1584-7.
doi: 10.1200/JCO.2011.39.9980.

A way forward on the medically appropriate use of white cell growth factors

Thomas J Smith 1 Bruce E Hillner  
Affiliations
  • PMID: 22370327
  •     46 References
  •     4 citations

No abstract available

Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.
J Clin Oncol, 1996 Feb 01; 14(2). PMID: 8636786
Highly Cited.
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.
Arnold L Potosky, Jennifer L Malin, +4 authors, Jane C Weeks.
J Natl Cancer Inst, 2011 Jun 15; 103(12). PMID: 21670423    Free PMC article.
Limits on Medicare's ability to control rising spending on cancer drugs.
Peter B Bach.
N Engl J Med, 2009 Jan 30; 360(6). PMID: 19176475
Highly Cited.
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
Donald A Berry, Constance Cirrincione, +9 authors, Eric P Winer.
JAMA, 2006 Apr 13; 295(14). PMID: 16609087    Free PMC article.
Highly Cited.
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Thomas J Smith, James Khatcheressian, +19 authors, Antonio C Wolff.
J Clin Oncol, 2006 May 10; 24(19). PMID: 16682719
Highly Cited.
Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.
Roy E Smith, John Bryant, +2 authors, National Surgical Adjuvant Breast and Bowel Project Experience.
J Clin Oncol, 2003 Mar 29; 21(7). PMID: 12663705
A randomized, crossover comparison of standard-dose versus low-dose lenograstim in the prophylaxis of post-chemotherapy neutropenia.
O Juan, J M Campos, +3 authors, V Alberola.
Support Care Cancer, 2001 Jun 30; 9(4). PMID: 11430419
Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer.
Gary H Lyman, Richard L Barron, Jaime L Natoli, Ross M Miller.
Crit Rev Oncol Hematol, 2011 Jun 04; 81(3). PMID: 21636289
Systematic Review.
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.
V Trillet-Lenoir, J Green, +7 authors, D Tomita.
Eur J Cancer, 1993 Jan 01; 29A(3). PMID: 7691119
Highly Cited.
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
P Bonomi, K Kim, +5 authors, D Johnson.
J Clin Oncol, 2000 Feb 02; 18(3). PMID: 10653877
Is health spending excessive? If so, what can we do about it?
Henry J Aaron, Paul B Ginsburg.
Health Aff (Millwood), 2009 Sep 10; 28(5). PMID: 19738241
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
Nicole M Kuderer, David C Dale, Jeffrey Crawford, Gary H Lyman.
J Clin Oncol, 2007 Jul 20; 25(21). PMID: 17634496
Highly Cited. Systematic Review.
Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
Scott D Ramsey, Zhimei Liu, +5 authors, Gary H Lyman.
Value Health, 2008 Aug 05; 12(2). PMID: 18673353
Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection.
Lillian Sung, Paul C Nathan, +2 authors, Joseph Beyene.
Ann Intern Med, 2007 Sep 19; 147(6). PMID: 17876022
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
Charles L Vogel, Marek Z Wojtukiewicz, +5 authors, Lee S Schwartzberg.
J Clin Oncol, 2005 Feb 19; 23(6). PMID: 15718314
Bending the cost curve in cancer care.
Thomas J Smith, Bruce E Hillner.
N Engl J Med, 2011 May 27; 364(21). PMID: 21612477    Free PMC article.
Highly Cited.
Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer.
Scott D Ramsey, Jeannine S McCune, +4 authors, Sean D Sullivan.
Am J Manag Care, 2010 Sep 30; 16(9). PMID: 20873955
Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives.
Marc L Citron.
Breast Care (Basel), 2008 Jan 01; 3(4). PMID: 21076605    Free PMC article.
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Luisa Bonilla, Irit Ben-Aharon, +3 authors, Salomon M Stemmer.
J Natl Cancer Inst, 2010 Nov 26; 102(24). PMID: 21098761    Free PMC article.
Systematic Review.
Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?
M Masutani, I Tsujino, +6 authors, T Horie.
Oncol Rep, 1999 Jul 30; 6(5). PMID: 10425301
Recombinant granulocyte colony stimulating factor in the treatment of small cell lung cancer: a long-term follow-up.
V Trillet-Lenoir, J A Green, +7 authors, J Matcham.
Eur J Cancer, 1995 Nov 01; 31A(12). PMID: 8562177
Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer.
Dawn L Hershman, Elizabeth T Wilde, +4 authors, Alfred I Neugut.
J Clin Oncol, 2012 Feb 09; 30(8). PMID: 22312106    Free PMC article.
Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
Andrea Ardizzoni, Vivianne C G Tjan-Heijnen, +12 authors, European Organization for Research and Treatment of Cancer-Lung Cancer Group.
J Clin Oncol, 2002 Sep 28; 20(19). PMID: 12351591
Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison.
G C Toner, J D Shapiro, +8 authors, J F Bishop.
J Clin Oncol, 1998 Dec 16; 16(12). PMID: 9850033
Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
Francesco Grossi, Marcello Tiseo.
Crit Rev Oncol Hematol, 2006 May 16; 58(3). PMID: 16697211
Review.
Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.
Gary H Lyman, David C Dale, +4 authors, Jeffrey Crawford.
J Clin Oncol, 2010 Apr 14; 28(17). PMID: 20385991
Systematic Review.
Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.
Eric J Ip, Annette Lee-Ma, Lawrence S Troxell, James Chan.
Am J Health Syst Pharm, 2008 Aug 12; 65(16). PMID: 18693211
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.
H Ozer, J O Armitage, +12 authors, American Society of Clinical Oncology.
J Clin Oncol, 2000 Oct 14; 18(20). PMID: 11032599
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Hyman B Muss, Donald A Berry, +7 authors, Cancer and Leukemia Group B Experience.
J Clin Oncol, 2007 Aug 21; 25(24). PMID: 17704418
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
J Crawford, H Ozer, +7 authors, G Rausch.
N Engl J Med, 1991 Jul 18; 325(3). PMID: 1711156
Highly Cited.
Small cell lung cancer.
Gregory P Kalemkerian, Wallace Akerley, +20 authors, National Comprehensive Cancer Network.
J Natl Compr Canc Netw, 2011 Oct 07; 9(10). PMID: 21975911
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Dawn Hershman, Alfred I Neugut, +5 authors, Victor R Grann.
J Natl Cancer Inst, 2007 Feb 08; 99(3). PMID: 17284714
Projections of the cost of cancer care in the United States: 2010-2020.
Angela B Mariotto, K Robin Yabroff, +2 authors, Martin L Brown.
J Natl Cancer Inst, 2011 Jan 14; 103(2). PMID: 21228314    Free PMC article.
Highly Cited.
Health care use and primary prophylaxis with colony-stimulating factors.
Sean D Sullivan, Scott D Ramsey, +3 authors, Jeannine S McCune.
Value Health, 2011 Mar 16; 14(2). PMID: 21402293
Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group.
A Font, A J Moyano, +7 authors, R Rosell.
Cancer, 1999 Mar 26; 85(4). PMID: 10091762
Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.
Nicole M Kuderer, Gary H Lyman.
J Natl Cancer Inst, 2011 Jun 15; 103(12). PMID: 21670422    Free PMC article.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
M S Aapro, J Bohlius, +10 authors, European Organisation for Research and Treatment of Cancer.
Eur J Cancer, 2010 Nov 26; 47(1). PMID: 21095116
Highly Cited. Systematic Review.
Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
Sophie Whyte, Katy L Cooper, +2 authors, Ron Akehurst.
Value Health, 2011 Jun 15; 14(4). PMID: 21669371
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia.
L C Hartmann, L K Tschetter, +9 authors, C G Moertel.
N Engl J Med, 1997 Jun 19; 336(25). PMID: 9187067
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
Claudio Praga, Jonas Bergh, +16 authors, David Rogers.
J Clin Oncol, 2005 Jun 18; 23(18). PMID: 15961765
Myeloid growth factors.
Jeffrey Crawford, Jeffrey Allen, +14 authors, National Comprehensive Cancer Network.
J Natl Compr Canc Netw, 2011 Sep 09; 9(8). PMID: 21900221
Cost of cancer care: issues and implications.
Neal J Meropol, Kevin A Schulman.
J Clin Oncol, 2007 Jan 11; 25(2). PMID: 17210937
Review.
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Julia Bohlius, Christine Herbst, +2 authors, Andreas Engert.
Cochrane Database Syst Rev, 2008 Oct 10; (4). PMID: 18843642    Free PMC article.
Systematic Review.
Advancing performance measurement in oncology.
Francis X Campion, Leanne R Larson, +2 authors, Michael N Neuss.
Am J Manag Care, 2011 Jul 08; 17 Suppl 5 Developing. PMID: 21711075
Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
S Hashino, M Morioka, +15 authors, M Asaka.
Int J Lab Hematol, 2008 Jul 31; 30(4). PMID: 18665826
Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.
Derek Weycker, Rich Barron, +3 authors, Andrew G Glass.
BMC Health Serv Res, 2014 Apr 29; 14. PMID: 24767095    Free PMC article.
Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.
Hartmut Link, J Nietsch, +2 authors, Supportive Care Group (ASORS) of the German Cancer Society (DKG).
Support Care Cancer, 2015 Jun 18; 24(1). PMID: 26081593
Practice Patterns for Older Adult Patients With Advanced Cancer: Physician Office Versus Hospital Outpatient Setting.
Allison Lipitz-Snyderman, Coral L Atoria, +2 authors, Katherine S Panageas.
J Oncol Pract, 2018 Dec 14; 15(1). PMID: 30543762    Free PMC article.
Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy.
Prasad L Gawade, Shuling Li, +4 authors, Brian D Bradbury.
Support Care Cancer, 2020 Jan 11; 28(9). PMID: 31919669    Free PMC article.